The median progression-free survival was @ months in the dabrafenib-trametinib group and @ months in the dabrafenib-only group ( hazard ratio for progression or death in the dabrafenib-trametinib group , @ ; @ % confidence interval -LSB- CI -RSB- , @ to @ ; P = @ ) .